A recent agreement orchestrated by U.S. President Donald Trump with major pharmaceutical companies is geared towards broadening coverage and reducing prices for popular weight-loss medications in the United States. The pact with Eli Lilly and Novo Nordisk is designed to extend Medicare coverage for Zepbound and Wegovy, two medications classified as GLP-1 receptor agonists. GLP-1 agonists, such as Wegovy and Ozempic, imitate the GLP-1 hormone to aid in managing diabetes and obesity by triggering insulin release, slowing stomach emptying, and curbing appetite.
In the U.S., access to these medications has been limited due to inconsistent insurance coverage and high costs, sometimes exceeding $500 per month for higher dosages. The announcement by President Trump is expected to significantly reduce costs starting next year, with a $50 copay for eligible individuals with severe obesity or related health issues. Additionally, the TrumpRx program will introduce lower prices for those without insurance, with drug prices commencing at approximately $350 and decreasing to $245 within two years.
Despite these reductions, Canadian pricing for GLP-1 drugs is already notably lower, taking currency exchange rates into account. Prices in Canada for medications like Ozempic and Wegovy range from $300 to $500 monthly. Novo Nordisk, the manufacturer of these drugs, may lose its market exclusivity in Canada in January, potentially leading to the introduction of generic versions. This shift could bring the cost down to under $100 for a similar strength of semaglutide product, as estimated by pharmaceutical pricing expert Mina Tadrous from the University of Toronto.
GLP-1 medications are highly sought-after in Canada, with significant costs to provincial drug plans. The country’s public drug plan spending has seen a substantial increase, particularly on antidiabetic medications like Ozempic, contributing to a substantial portion of the rise in drug expenses. The potential decrease in prices could prompt more Canadians to seek prescriptions, even for off-label uses not covered by private insurance plans.
Some patients currently pay out-of-pocket for GLP-1 drugs, with Wegovy not covered by provincial governments but possibly included in private insurance policies. Dr. Gupta emphasized the possibility of easier access to semaglutide if it becomes generic, offering more options for overweight or obese patients. Nevertheless, the decision to prescribe these medications for unapproved uses will depend on individual physicians.